SANOFI-AVENTIS U.S. LLC
BiotechSANOFI-AVENTIS U.S. LLC is a biotechnology company focused on Metabolic, Oncology, Cardiovascular. Key products include Toujeo.
SANOFI-AVENTIS U.S. LLC at a Glance
- Fast trial execution (19 months median completion)
SANOFI-AVENTIS U.S. LLC's Key Drugs
SANOFI-AVENTIS U.S. LLC's core commercial portfolio centers on Toujeo, MERILOG SOLOSTAR, spanning Metabolic and Oncology — its most strategically important drugs approved in the last 15 years.
SANOFI-AVENTIS U.S. LLC's Recent FDA Approvals
SANOFI-AVENTIS U.S. LLC secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
SANOFI-AVENTIS U.S. LLC's Therapeutic Areas
SANOFI-AVENTIS U.S. LLC's approved drugs and pipeline span 5 therapeutic areas, led by Metabolic and Oncology, across 1 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
SANOFI-AVENTIS U.S. LLC's Top Competitors
SANOFI-AVENTIS U.S. LLC's closest competitors by therapeutic-area and drug-target overlap include Novartis, AstraZeneca, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
SANOFI-AVENTIS U.S. LLC Pipeline Snapshot
SANOFI-AVENTIS U.S. LLC has 490 active clinical programs from ClinicalTrials.gov — 157 Phase 3, 103 Phase 2 and 230 Phase 1.
Phase 3 Readout Calendar Pro
8 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Toujeo leads revenue
- • 2 key drugs tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 224/312 completed
- • Speed: 19 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2015-02-24
- Latest
- 2025-02-14
- Applications
- 2
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges